Malignant mesothelioma is a rare and aggressive cancer with limited therapeutic options.
Author: admin
Our Four Leading Principles:
Innovation
Quality
Globalization
Competitiveness
Fidia signed a binding agreement with Sanofi for the acquisition of a portfolio of anti-inflammatory drugs.
Our Four Leading Principles:
Innovation
Quality
Globalization
Competitiveness
The health, well-being and safety of the people we engage with, including you, our customers, partners, and suppliers, as well as all of our employees, continues to be a top priority for Fidia.
Our Four Leading Principles:
Innovation
Quality
Globalization
Competitiveness
Fidia has implemented a series of measures, to minimize any potential risks related with the COVID-19 outbreak, guaranteeing full operations in, from and to the factories, as well as transports of goods and supply of materials.
Our Four Leading Principles:
Innovation
Quality
Globalization
Competitiveness
Florham Park, N.J., December 2, 2019 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid-based products and its wholly owned subsidiary, Fidia Pharma USA Inc., introduce in the US, TRILURON™ (sodium hyaluronate).
Our Four Leading Principles:
Innovation
Quality
Globalization
Competitiveness
CartiJoint™ FORTE is the First Product in Fidia’s New Dietary Supplement Portfolio; Uniquely formulated with bioactive Bio-Curcumin Curcugreen™
Our Four Leading Principles:
Innovation
Quality
Globalization
Competitiveness
Florham Park, NJ, March 12, 2019 – NuDYN™ is the First Product in Fidia’s New Orthobiologics Portfolio; A Novel Acellular Amnion-Derived Injectable Allograft
Our Four Leading Principles:
Innovation
Quality
Globalization
Competitiveness
Efficacy and tolerability results with Oncofid®P-B in patients with papillary bladder cancer No new drug treatments for primary or recurrent papillary bladder cancer in 15 years Oncofid®P-B is a Paclitaxel-Hyaluronan Bioconjugate developed and patented by Fidia farmaceutici, a leading Italian pharmaceutical multinational company Copenhagen, March 18, 2018 – Fidia farmaceutici today announced the positive results […]
Our Four Leading Principles:
Innovation
Quality
Globalization
Competitiveness
Global viscosupplementation market is anticipated to increase to over $2.64 billion by 2021
PARSIPPANY, N.J., June 28, 2017 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronan (HA)-based products, and its wholly owned subsidiary, FIDIA PHARMA USA Inc., are projecting continued growth in 2017. The global viscosupplementation market is anticipated
Our Four Leading Principles:
Innovation
Quality
Globalization
Competitiveness
PARSIPPANY, NJ, May 8, 2017 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronan (HA) – based products and its wholly owned subsidiary, Fidia Pharma USA Inc., announces their presence at the American Medical Society for Sports Medicine (AMSSM) 2017 Annual Meeting with an educational symposium on Thursday, May […]